Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit
On June 18, 2024, Tenaya Therapeutics, a clinical-stage biotechnology company focused on developing therapies for heart disease, announced its participation in the TD Cowen Genetic Medicines & RNA Summit.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
On June 18, 2024, Tenaya Therapeutics, a clinical-stage biotechnology company focused on developing therapies for heart disease, announced its participation in the TD Cowen Genetic Medicines & RNA Summit. The company's CEO, Faraz Ali, will present on June 21, 2024, at 11:20 am ET. The live presentation will be webcast, accessible from the Investors section of Tenaya's website, with a replay available for 30 days post-conference.
Details
News Market Reaction – TNYA
The recorded move for TNYA in the trading session of this news was +0.95%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Chief Executive Officer, will participate in the TD Cowen Genetic Medicines & RNA Summit on Friday, June 21, 2024, at 11:20 am ET.
The live presentation will be webcast and may be accessed from the Investors section of Tenaya’s website. A replay of the webcast will be available on the Tenaya website for approximately 30 days following the conference.
About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Leveraging its integrated and interrelated Gene Therapy, Cellular Regeneration and Precision Medicine platforms and proprietary core capabilities, the company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. Tenaya’s most advanced candidates include TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), and TN-301, a small molecule HDAC6 inhibitor being initially developed for heart failure with preserved ejection fraction (HFpEF). Tenaya also has multiple early-stage programs progressing through preclinical development. For more information, visit www.tenayatherapeutics.com.
| Contacts | Investors |
| Michelle Corral | Anne-Marie Fields |
| VP, Corporate Communications and Investor Relations | Precision AQ |
| IR@tenayathera.com | Annemarie.fields@precisionaq.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.